Pregabalin
Product Images NDC 60760-509

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-509). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pre (Pregabalin 60760 509 60)

Pregabalin Capsules 300 mg label with quantity of 60 capsules. The label includes the product NDC 60760-509-60, RX number, lot number, and expiration date (all obscured). Manufactured by ScieGen Pharmaceuticals, Inc., Hauppauge, NY, and packaged by St Mary's Medical Park Pharmacy, Oro Valley, AZ. Storage instructions specify controlled room temperature 15°-30°C (59°-86°F).*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 25 mg, 100 mg, and 200 mg three times a day, compared to placebo. The legend identifies each treatment group by line style.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph showing percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day to placebo. The graph displays a higher percentage of patient improvement with Pregabalin across the range of pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. It compares pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day with a placebo group, with each group represented by a different line style.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph compares effectiveness of the two Pregabalin doses against placebo over varying levels of pain improvement.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph comparing the percent of patients improved against the percent improvement in pain from baseline, for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The y-axis represents the percent of patients improved, and the x-axis shows the percent improvement in pain, ranging from 0 to 100 percent. Vertical reference lines are marked at specific improvement points.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates in percentage between placebo and different dosages of a treatment across two studies labeled E1 and E3. The x-axis shows treatment groups including placebo, varying dosages per day, and dosing frequency. The y-axis represents responder rate percentage from 0% to 60%. Statistically significant differences from placebo are noted with asterisks.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A dose-response graph depicting seizure reduction as median percent change from baseline across different doses in mg/day. The graph compares results from four studies labeled E1 BD, E2 TID, E3 BD, and E3 TID with symbols indicating statistical significance (p-values). The x-axis represents dose in mg/day and the y-axis shows seizure reduction percentages.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph depicting percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. Four curves compare Pregabalin daily doses of 800 mg, 450 mg, 300 mg, and placebo, showing varying levels of patient improvement over a range of pain reduction percentages.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without LTR over a period of 180 days for Pregabalin versus Placebo. The y-axis shows the estimated percentage from 0% to 100%, while the x-axis represents days from 0 to 180. The Pregabalin group shows a higher percentage of subjects without LTR compared to the Placebo group throughout the study period.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved with Pregabalin versus placebo over a range of percent improvement from baseline to Week 12 BOCF. The vertical axis shows percent of subjects improved, and the horizontal axis shows percent improvement from baseline. The solid line represents Pregabalin, and the dotted line represents placebo, with Pregabalin showing consistently higher improvement percentages.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved from baseline to week 16 BOCF for Pregabalin versus Placebo. The x-axis represents the percent improvement from 0 to 100, and the y-axis shows the percent of subjects improved from 0 to 100. The solid line represents Pregabalin, while the dashed line represents Placebo, showing higher improvement percentages for Pregabalin across the range.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A mathematical formula panel showing the calculation for creatinine clearance (CLcr). The formula is: CLcr = (140 minus age in years) times weight in kg, divided by 72 times serum creatinine in mg/dL, with a multiplication factor of 0.85 for female patients.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of the active ingredient Pregabalin, showing its molecular configuration with an amino group (NH2) and carboxylic acid group (CO2H) attached to a branched carbon chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.